7 November 2023
\n \n \n \nThe Global Health Network and the British Society for Antimicrobial Chemotherapy (BSAC) have signed a Memorandum of Understanding (MoU) establishing a framework for collaboration that can maximise the impact of shared antimicrobial resistance education, policy and advocacy efforts.
\n \n\n \n \n6 November 2023
\n \n \n \nScientific advisors to the International Pandemic Preparedness Secretariat (IPPS) visited the University of Oxford\u2019s vaccine laboratories as part of a two-day meeting of the global coalition.
\n \n\n \n \n3 November 2023
\n \n \n \nThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford announced the launch of a new project to initiate early development of prototype vaccines against the Jun\u00edn virus. This is the first project to be initiated under CEPI and the University of Oxford\u2019s strategic partnership to accelerate global pandemic preparedness efforts.
\n \n\n \n \n2 November 2023
\n \n \n \nThe AELIX-002 study group research was awarded the European Hector Research Award in HIV for research on the therapeutic vaccine against HIV. The researchers include Prof Tom\u00e1\u0161 Hanke, Professor of Vaccine Immunology at the Jenner Institute at NDM.
\n \n\n \n \n1 November 2023
\n \n \n \nNDM\u2019s Oxford University Clinical Research Unit in Viet Nam will be a part of a new initiative aimed at developing a strategic roadmap for Ho Chi Minh City to become a regional Health Innovation Hub. The project, supported by a \u00a375,000 grant from the UK Government, is a strategic move to transform Ho Chi Minh City into ASEAN's leading health innovation centre.
\n \n\n \n \n30 October 2023
\n \n \n \nThe Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial, which discovered four effective treatments for COVID-19, has now expanded to investigate treatments for influenza (flu). The RECOVERY trial is a collaboration between the Nuffield Department of Medicine and the Nuffield Department of Population Health.
\n \n\n \n \n26 October 2023
\n \n \n \nThe Broad One Health Endectocide-based Malaria Intervention in Africa project (BOHEMIA) begins its mass drug administration (MDA) activities in Kenya\u2019s Kwale County. BOHEMIA is a consortium of multiple international organisations including the Centre for Tropical Medicine and Global Health at NDM.
\n \n\n \n \n20 October 2023
\n \n \n \nIn collaboration with Ho Chi Minh City's healthcare sector, NDM's Oxford University Clinical Research Unit has successfully identified the primary agent causing the outbreak of pink eye disease. Testings revealed an unexpected finding: enterovirus was the primary agent, contrary to previous reports from Vietnam wherein adenovirus was the culprit.
\n \n\n \n \n10 October 2023
\n \n \n \nToday Oxford University has launched a new global collaboration backed by \u00a38 million funding from UK Research and Innovation (UKRI). The project will be spearheaded by Professor Teresa Lambe, Professor of Vaccinology and Immunology and Calleva Head of Vaccine Immunology in the Department of Paediatrics and Professor Paul Klenerman, Sidney Truelove Professor of Gastroenterology and Director of the Translational Gastroenterology Unit at NDM, both of whom are Principal Investigators at NDM\u2019s Pandemic Sciences Institute.
\n \n\n \n \n2 October 2023
\n \n \n \nThe World Health Organization\u2019s Strategic Advisory Group of Experts (SAGE) and Malaria Policy Advisory Group (MPAG) have recommended Oxford\u2019s R21/Matrix-M\u2122 malaria vaccine for use. The highly effective vaccine developed by the Jenner Institute and the Serum Institute of India has demonstrated high efficacy with a reassuring safety profile.
\n \n\n \n \n28 September 2023
\n \n \n \nA delegation from the Beijing Center for Disease Prevention and Control (Beijing CDC) visited the Chinese Academy of Medical Sciences Oxford Institute (COI) at NDM recently.
\n \n\n \n \n18 September 2023
\n \n \n \nA new clinical trial to find a vaccine to protect people against Middle East Respiratory Syndrome (MERS) launched on 15 September 2023. This is the third Phase I clinical trial of the ChAdOx1 MERS vaccine, developed by researchers at the Pandemic Sciences Institute. It is the first trial in older people.
\n \n\n \n \n15 September 2023
\n \n \n \nResearchers at the Pandemic Sciences Institute (PSI) are closely monitoring the current outbreak of deadly Nipah virus in Kerala, India. To date, there have been five confirmed cases and two deaths reported, with many of those affected being family members of the first patient. The Institute has collaborations with scientists involved in the response, including virologists at the National Institute of Virology in Pune.
\n \n\n \n \n11 September 2023
\n \n \n \nA University of Oxford study has administered a new vaccine against tick-borne virus Crimean-Congo haemorrhagic fever (CCHF) to volunteers for the first time. CCHF is on the World Health Organization's top priority watchlist for viruses that could cause a future pandemic, and yet no approved vaccines currently exist.
\n \n\n \n \n8 September 2023
\n \n \n \nWe are delighted to announce that six researchers have been awarded the Professor title, in recognition of their research achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.
\n \n\n \n \n1 September 2023
\n \n \n \nOne year on from the launch of the Ling Felce Award for the training of researchers in Oxford, we reflect on the impact of the award and the generosity of our donors.
\n \n\n \n \n30 August 2023
\n \n \n \nThe Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have entered into a strategic partnership to accelerate the development of safe, effective and globally accessible vaccines to counter the threat of future pandemics.
\n \n\n \n \n11 August 2023
\n \n \n \nFour major clinical trial networks, including Oxford University Clinical Research Unit, The Global Health Network, hosted by NDM\u2019s Centre for Tropical Medicine and Global Health, based in low-resource settings are embarking on an exciting partnership with the Good Clinical Trials Collaborative (GCTC) to enhance clinical research in low-resource settings.
\n \n\n \n \n3 August 2023
\n \n \n \nThe KEMRI-Wellcome Trust Research Programme from NDM has participated in a new European-African consortium to improve the way infections in newborns are treated. This project, called SNIP-AFRICA, aims to reduce mortality among neonates in hospitals with sepsis in Africa, in an era of increasing antimicrobial resistance.
\n \n\n \n \n27 July 2023
\n \n \n \nPSI and the WHO Hub for Pandemic and Epidemic Intelligence will collaborate to improve the detection and tracking of infectious diseases.
\n \n\n \n \n